Navigation Links
New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Cytogen Corporation (NASDAQ: CYTO) today reported results from clinical trials demonstrating that QUADRAMET (samarium Sm-153 lexidronam injection) can be safely administered to prostate cancer patients who are also receiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis). Clinical data also support further evaluation of the combination regimen for the treatment of prostate cancer in a Phase 2 program. The results were presented and/or published at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois and are summarized herein.

ASCO Abstracts

"Phase 1 study of docetaxel and (153)Sm-lexidronam repetitively administered for castrate metastatic prostate cancer" by Morris M.J. et al. Memorial Sloan-Kettering Cancer Center (Abstract No. 5152, Poster No. L6)

Despite a favorable safety and efficacy profile, the routine and repetitive use of QUADRAMET for the palliation of pain from cancer that has spread to the bone has historically been limited in combination settings due to concerns regarding the potential for overlapping toxicities.

Accordingly, the objective of this open-label Company-sponsored Phase 1 study was to evaluate the safety and feasibility of repetitive co-administration of docetaxel and QUADRAMET in twenty-eight hormone-refractory prostate cancer patients with progressive disease and at least three bone metastases confirmed through a bone scan. In addition, early clinical data suggest synergistic effects between QUADRAMET and chemotherapy; therefore, as a secondary objective the anti-tumor effects of the combined regimen were also assessed.

Patients received repeated escalating doses of the combination of QUADRAMET (at doses up to the full FDA-approved doses of 1.0 mCi/kg, given every six to nine weeks) and docetaxel (at doses up to 75 mg/m2 given every three weeks). Dose
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
2. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
8. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
9. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
10. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data for Cytogen QUADRAMET Reported Annual ASCO Meeting
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...
... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...
Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... breast cancer researcher and assistant member at Moffitt ... General Electric,s $100 million healthymagination Challenge to develop ... to determine if they are predisposed to develop ... grant awarding initiative focuses on "finding new ideas ...
... Researchers at Moffitt Cancer Center and colleagues have ... strong concerns about their ability to have children ... health-related quality-of-life survey tools used to elicit answers ... these concerns. Parents, who often answer survey questions ...
... Center have placed new emphasis on gathering data on cancer ... focus is on gathering and using that data to develop ... treatment and for cancer survivors. Much of the quality ... in Moffitt,s Department of Health Outcomes & Behavior. "Among ...
... , FRIDAY, April 27 (HealthDay News) -- People with chronic ... be able to sleep better, according to a new study. ... basis. The study included 214 people with chronic jaw ... patients were white females, whose average age was 34. ...
... April 27 (HealthDay News) -- People undergoing outpatient surgery should ... to a new study that finds the risk is higher ... older or obese. The University of Michigan researchers found ... clot after outpatient surgery. More than 60 percent of ...
... and Rebecca Moores Professor of Psychology, has earned the ... symbol of overall career excellence and the highest honor ... carries a cash prize of $10,000. "The Farfel ... that we may have as professionals, as mentors, teachers, ...
Cached Medicine News:Health News:Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks 2Health News:Moffitt researchers find adolescents with cancer concerned about their future reproductive health 2Health News:Moffitt researchers find adolescents with cancer concerned about their future reproductive health 3Health News:Moffitt Cancer Center researchers: Quality of life as important as quantity of life 2Health News:Moffitt Cancer Center researchers: Quality of life as important as quantity of life 3Health News:Adjusting Your Attitude About Chronic Pain May Help You Sleep 2Health News:Blood Clot Risk for Outpatients Needs More Attention: Study 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: